NYSEAMERICAN:BPMX Biopharmx (BPMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Biopharmx Stock (NYSEAMERICAN:BPMX) Get Biopharmx alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume336,508 shsAverage Volume2.15 million shsMarket Capitalization$111.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioPharmX Corporation was a specialty pharmaceutical company focused on developing topical treatments for dermatological conditions. Its research programs centered on formulations designed to deliver established active pharmaceutical ingredients directly to the skin. The company’s primary development programs included BPX-01, a topical minocycline formulation investigated for the treatment of moderate-to-severe acne, and BPX-04, a related topical product studied for rosacea. BioPharmX also developed proprietary drug-delivery technology intended to support the formulation and administration of topical medicines. BioPharmX was based in the United States and operated primarily as a development-stage biotechnology company. Publicly available historical information about its later operations, leadership, and commercial activities is limited.AI Generated. May Contain Errors. Read More Receive BPMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMX Stock News HeadlinesBioPharmX (BPMX) Stock Soars on Potential 'Breakthrough' Acne TreatmentJuly 8, 2023 | thestreet.comForm 424B5 Timber Pharmaceuticals, - StreetInsider.comOctober 3, 2022 | streetinsider.comElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.October 26 at 1:00 AM | Brownstone Research (Ad)Outlook on the Acne Treatment Global Market, to 2027 - Rising Public Knowledge of Cosmetic Acne Treatments is Driving Growth - Yahoo FinanceSeptember 22, 2022 | finance.yahoo.comGlobal Acne Treatment Market, By Therapeutic Class, By Formulation, By Type, By Acne Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 - GlobeNewswireJuly 19, 2022 | globenewswire.comTimber Pharmaceuticals, Inc. (TMBR) Stock Price Today, Quote & News - Seeking AlphaJuly 17, 2022 | seekingalpha.comForm DEF 14A Vivos Therapeutics, Inc. For: Jul 14 - StreetInsider.comJuly 14, 2022 | streetinsider.comManagement's Discussion and Analysis of the Results of Operations - Marketscreener.comMay 13, 2022 | marketscreener.comMSee More Headlines BPMX Stock Analysis - Frequently Asked Questions How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share for the quarter, topping analysts' consensus estimates of ($2.64) by $0.96. When did Biopharmx's stock split? Shares of Biopharmx reverse split on the morning of Tuesday, May 19th 2020.The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Biopharmx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biopharmx investors own include Novavax (NVAX), TNF Pharmaceuticals (TNFA), Jaguar Animal Health (JAGX), Atossa Genetics (ATOS), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX) and Micron Technology (MU). Company Calendar Last Earnings12/10/2019Today10/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CIKN/A Webwww.biopharmx.com Phone+1-650-8895020FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,278,000Free FloatN/AMarket Cap$111.86 million OptionableNot Optionable BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSEAMERICAN:BPMX) was last updated on 5/18/2020 by MarketBeat.com Staff. From Our PartnersExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | SponsoredFinally… options made simpleIan Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big ...TradeWins | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biopharmx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Biopharmx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.